Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 9

Results For "Pharmaceuticals"

1374 News Found

Alembic Pharmaceuticals gets USFDA final approval for Dabigatran Etexilate capsules
Drug Approval | June 19, 2024

Alembic Pharmaceuticals gets USFDA final approval for Dabigatran Etexilate capsules

Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients


Health Minister J P Nadda takes review meeting of Department of Pharmaceuticals
Policy | June 17, 2024

Health Minister J P Nadda takes review meeting of Department of Pharmaceuticals

Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department


Torrent Pharmaceuticals gets Form 483 with 5 observations for Indrad facility
Drug Approval | June 13, 2024

Torrent Pharmaceuticals gets Form 483 with 5 observations for Indrad facility

There was no observation related to data integrity reported


AstraZeneca completes acquisition of Fusion Pharmaceuticals
News | June 05, 2024

AstraZeneca completes acquisition of Fusion Pharmaceuticals

This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs


Alembic Pharmaceuticals receives USFDA final approval for Sacubitril and Valsartan Tablets
Drug Approval | May 30, 2024

Alembic Pharmaceuticals receives USFDA final approval for Sacubitril and Valsartan Tablets

Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death


IOL Chemicals and Pharmaceuticals posts Q4 FY24 consolidated PAT at Rs. 27.62 Cr
News | May 15, 2024

IOL Chemicals and Pharmaceuticals posts Q4 FY24 consolidated PAT at Rs. 27.62 Cr

The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024


AbbVie and Gilgamesh Pharmaceuticals collaborate to develop next-gen therapies for psychiatric disorders
News | May 14, 2024

AbbVie and Gilgamesh Pharmaceuticals collaborate to develop next-gen therapies for psychiatric disorders

Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders


Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25
Drug Approval | May 10, 2024

Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25

Receives 3 final and 2 tentative product approvals thus far in Q1FY25


Alembic Pharmaceuticals posts Q4 FY24 PAT at Rs. 178.21 Cr
News | May 10, 2024

Alembic Pharmaceuticals posts Q4 FY24 PAT at Rs. 178.21 Cr

The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024


WACKER expands production capacity for biopharmaceuticals in San Diego
News | May 08, 2024

WACKER expands production capacity for biopharmaceuticals in San Diego

Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA